Regeneron Pharmaceuticals Inc (NAS:REGN)
$ 975.28 7.28 (0.75%) Market Cap: 107.46 Bil Enterprise Value: 98.84 Bil PE Ratio: 28.81 PB Ratio: 3.98 GF Score: 94/100

Q3 2020 Regeneron Pharmaceuticals Inc Earnings Call Transcript

Nov 05, 2020 / 01:30PM GMT
Release Date Price: $588.81 (+0.28%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Regeneron Pharmaceuticals Third Quarter 2020 Earnings Call. (Operator Instructions)

I would now like to hand the conference over to your speaker Justin Holko. Please go ahead, sir.

Justin Holko
Regeneron Pharmaceuticals, Inc. - VP of IR

Thank you, Deborah. Good morning, good afternoon and good evening to everyone listening around the globe. Thank you for your interest in Regeneron Pharmaceuticals, and welcome to the third quarter 2020 conference call. An archive of this webcast will be available on our website. Joining me on the call today are Dr. Leonard Schleifer, Founder, President and Chief Executive Officer; Dr. George Yancopoulos, Co-Founder, President and Chief Scientific Officer; Marion McCourt, Senior Vice President and Head of Commercial; and Bob Landry, Executive Vice President and Chief Commercial -- Chief Financial Officer. After our prepared remarks, we will open the call for Q&A.

I would also like to remind you that remarks made on today's call include

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot